| Medical and Health Sciences | 2021-2025 | 180 | CN 18 | 99.97 |
| Biological Sciences | 2021-2025 | 137 | CN 54 | 99.88 |
| Epidemiology | Lifetime | 352 | CN 10 | 99.57 |
| Molecular Biology | Lifetime | 927 | CN 47 | 99.49 |
| Pathology and Forensic Medicine | Lifetime | 203 | CN 2 | 99.26 |
| Oncology | Lifetime | 489 | CN 13 | 99.10 |
| Immunology | Lifetime | 377 | CN 8 | 99.05 |
| Cancer Research | Lifetime | 256 | CN 17 | 98.51 |
| Pharmacology | Lifetime | 286 | CN 20 | 97.33 |
| Complementary and Alternative Medicine | Lifetime | 566 | CN 47 | 95.97 |
| Health, Toxicology and Mutagenesis | Lifetime | 739 | CN 134 | 96.44 |
| Hepatology | Lifetime | 489 | CN 25 | 94.99 |
| Obstetrics and Gynecology | Lifetime | 869 | CN 13 | 85.92 |
| Endocrine and Autonomic Systems | Lifetime | 797 | CN 10 | 80.34 |
| Molecular Biology | 2021-2025 | 104 | CN 48 | 99.59 |
| Epidemiology | 2021-2025 | 72 | CN 8 | 99.58 |
| Immunology | 2021-2025 | 46 | CN 10 | 99.05 |
| Pathology and Forensic Medicine | 2021-2025 | 52 | CN 1 | 98.93 |
| Health, Toxicology and Mutagenesis | 2021-2025 | 187 | CN 72 | 97.26 |
| Oncology | 2021-2025 | 307 | CN 33 | 97.20 |
| Medical Physiology | 2021-2025 | 357 | CN 21 | 95.16 |
| Cancer Research | 2021-2025 | 141 | CN 48 | 92.76 |
| Business and International Management | 2021-2025 | 90 | CN 22 | 75.12 |
| Hepatology | 2021-2025 | 276 | CN 23 | 82.13 |
| MicroRNA in disease regulation | Lifetime | 106 | CN 31 | 99.45 |
| Liver Disease Diagnosis and Treatment | Lifetime | 208 | CN 8 | 99.67 |
| Liver physiology and pathology | Lifetime | 50 | CN 4 | 99.30 |
| Extracellular vesicles in disease | Lifetime | 84 | CN 21 | 98.93 |
| Cancer-related molecular mechanisms research | Lifetime | 270 | CN 122 | 98.95 |
| Circular RNAs in diseases | Lifetime | 120 | CN 66 | 99.01 |
| Drug-Induced Hepatotoxicity and Protection | Lifetime | 97 | CN 2 | 99.01 |
| Immune Cell Function and Interaction | Lifetime | 597 | CN 13 | 99.23 |
| Autophagy in Disease and Therapy | Lifetime | 168 | CN 20 | 98.77 |
| Alcohol Consumption and Health Effects | Lifetime | 186 | CN 5 | 98.26 |
| RNA modifications and cancer | Lifetime | 901 | CN 120 | 98.34 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 293 | CN 9 | 98.28 |
| Diet, Metabolism, and Disease | Lifetime | 334 | CN 9 | 98.25 |
| Lymphoma Diagnosis and Treatment | Lifetime | 770 | CN 11 | 98.20 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 932 | CN 30 | 98.07 |
| Birth, Development, and Health | Lifetime | 780 | CN 21 | 97.95 |
| Endoplasmic Reticulum Stress and Disease | Lifetime | 404 | CN 16 | 97.33 |
| Immune cells in cancer | Lifetime | 620 | CN 74 | 96.85 |
| Viral-associated cancers and disorders | Lifetime | 504 | CN 19 | 97.38 |
| Heavy Metal Exposure and Toxicity | Lifetime | 467 | CN 47 | 97.24 |
| Phagocytosis and Immune Regulation | Lifetime | 251 | CN 13 | 95.74 |
| NF-κB Signaling Pathways | Lifetime | 862 | CN 57 | 93.29 |
| Pregnancy and Medication Impact | Lifetime | 819 | CN 16 | 92.89 |
| Fibroblast Growth Factor Research | Lifetime | 700 | CN 45 | 92.11 |
| TGF-β signaling in diseases | Lifetime | 885 | CN 71 | 90.02 |
| Macrophage Migration Inhibitory Factor | Lifetime | 796 | CN 47 | 82.38 |
| Immune Cell Function and Interaction | 2021-2025 | 29 | CN 5 | 99.34 |
| Liver Disease Diagnosis and Treatment | 2021-2025 | 125 | CN 11 | 99.31 |
| Endoplasmic Reticulum Stress and Disease | 2021-2025 | 16 | CN 4 | 97.72 |
| Immune cells in cancer | 2021-2025 | 79 | CN 45 | 98.01 |
| Autophagy in Disease and Therapy | 2021-2025 | 53 | CN 23 | 97.40 |
| Extracellular vesicles in disease | 2021-2025 | 127 | CN 80 | 97.30 |
| Alcohol Consumption and Health Effects | 2021-2025 | 40 | CN 3 | 97.82 |
| Birth, Development, and Health | 2021-2025 | 209 | CN 23 | 96.23 |
| Heavy Metal Exposure and Toxicity | 2021-2025 | 168 | CN 65 | 93.94 |
| MicroRNA in disease regulation | 2021-2025 | 588 | CN 360 | 93.93 |
| Liver physiology and pathology | 2021-2025 | 85 | CN 35 | 91.55 |
| Drug-Induced Hepatotoxicity and Protection | 2021-2025 | 109 | CN 16 | 93.12 |
| Spine and Intervertebral Disc Pathology | 2021-2025 | 986 | CN 209 | 91.31 |
| Effects and risks of endocrine disrupting chemicals | 2021-2025 | 679 | CN 242 | 85.60 |
| Cancer Research and Treatments | 2021-2025 | 629 | CN 262 | 82.42 |
| Lipid metabolism and disorders | 2021-2025 | 254 | CN 49 | 81.26 |
| Peroxisome Proliferator-Activated Receptors | 2021-2025 | 326 | CN 109 | 75.41 |
| Phagocytosis and Immune Regulation | 2021-2025 | 458 | CN 188 | 75.24 |
| Viral-associated cancers and disorders | 2021-2025 | 926 | CN 195 | 77.75 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 745 | CN 229 | 70.29 |
| Pregnancy-related medical research | 2021-2025 | 860 | CN 94 | 66.22 |
| Biomedical Research and Pathophysiology | 2021-2025 | 250 | CN 29 | 65.66 |
| Traditional Chinese Medicine Analysis | 2021-2025 | 851 | CN 750 | 64.48 |
| Sphingolipid Metabolism and Signaling | 2021-2025 | 687 | CN 95 | 59.69 |